Core Insights - Teva Pharmaceutical reported adjusted earnings of 78 cents per share on $4.48 billion in third-quarter sales, surpassing analyst expectations of 68 cents per share and $4.38 billion in sales [1] - The company raised its sales guidance for the drug Austedo to $2.05 billion to $2.15 billion, while lowering the low end of its full-year sales outlook by $200 million to a range of $16.8 billion to $17 billion [2] - Teva's stock surged 12% in premarket trading, breaking out of a cup-with-handle base and returning to its buy zone [3] Financial Performance - Teva's third-quarter sales of $4.48 billion represent an increase from $4.33 billion in the same period last year [1] - The adjusted earnings guidance for the full year has been raised to a range of $2.55 to $2.65 per share, compared to analyst expectations of $2.61 per share [2] Stock Market Activity - Teva's stock price increased to $22.91 after the earnings report, indicating strong market performance [3] - The stock had previously dipped below its entry point but managed to return to the buy zone, which extends up to $20.98 [3]

Core Insights - Teva Pharmaceutical Industries Ltd. reported third-quarter earnings that exceeded expectations, driven by strong sales of innovative therapies and an improved full-year outlook, resulting in a share price surge of over 17% in intra-day trading [1] Financial Performance - The company posted adjusted earnings of $0.78 per share, surpassing analyst forecasts of $0.68 [1] - Revenue increased by 3% year over year to $4.48 billion, exceeding the consensus estimate of $4.36 billion, with 1% growth in local currency [1] Innovative Medicine Portfolio - Teva's innovative medicine portfolio, including AUSTEDO, AJOVY, and UZEDY, saw segment revenue rise by 33% year over year in local currency to $830 million [2] - AUSTEDO was the primary driver of growth, achieving $618 million in global sales, reflecting a 38% increase in local currency [2] Future Outlook - Based on strong momentum, Teva raised its 2025 AUSTEDO revenue forecast by $50 million to $100 million, establishing a new target range of $2.05 billion to $2.15 billion [3] - The company tightened its full-year revenue guidance to a range of $16.8 billion to $17.0 billion and raised the low end of its adjusted EPS range to $2.55–$2.65 from $2.50–$2.65 [3] Operational Efficiency - Teva's non-GAAP operating margin improved to 28.9%, an increase of 86 basis points from the previous year, keeping the company on track to achieve its 30% target by 2027 under its "Pivot to Growth" strategy [4]

Revenue Performance - Revenues in Q3 2025 were $4,480 million, a 3% increase in U.S. dollars and 1% in local currency compared to Q3 2024, driven by higher revenues from AUSTEDO and generic products[331] - The U.S. segment generated revenues of $2,483 million, a 12% increase, and segment profit of $937 million, a 25% increase compared to Q3 2024[331] - The Europe segment reported revenues of $1,235 million, a 2% decrease in U.S. dollars and 10% in local currency, with segment profit down 19% compared to Q3 2024[331] - The International Markets segment had revenues of $557 million, a 9% decrease in U.S. dollars and 10% in local currency, with segment profit decreasing by 13% compared to Q3 2024[331] - Total revenues for the company in Q3 2025 were $4,480 million, an increase of 3% in U.S. dollars compared to Q3 2024[415] Profitability Metrics - Gross profit margin improved to 51.4% in Q3 2025, up from 49.6% in Q3 2024[331] - Operating income was $882 million in Q3 2025, compared to an operating loss of $51 million in Q3 2024[331] - Gross profit for the company in Q3 2025 was $2,304 million, a 7% increase from $2,148 million in Q3 2024, with a gross profit margin of 51.4%[417] - In Q3 2025, net income attributable to Teva was $433 million, a significant recovery from a net loss of $437 million in Q3 2024[440] - Profit from the Europe segment decreased by 19% to $303 million in Q3 2025, down from $373 million in Q3 2024, mainly due to lower gross profit and higher S&M expenses[390] Research and Development (R&D) Expenses - R&D expenses increased by 7% to $256 million in Q3 2025, compared to $240 million in Q3 2024[331] - R&D expenses in the U.S. segment for Q3 2025 were $161 million, a 6% increase from $151 million in Q3 2024[368] - R&D expenses for the Europe segment increased by 12% to $62 million in Q3 2025, compared to $55 million in Q3 2024[387] - R&D expenses for the International Markets segment decreased by 4% to $26 million in Q3 2025, compared to $27 million in Q3 2024[407] - Research and development (R&D) expenses for the United States segment in the first nine months of 2025 were $467 million, a 2% decrease from $475 million in the same period of 2024[456] Selling and Marketing (S&M) Expenses - S&M expenses in the U.S. segment for Q3 2025 were $278 million, an 8% increase from $259 million in Q3 2024, mainly due to promotional activities[369] - S&M expenses for the Europe segment rose by 11% to $225 million in Q3 2025, up from $203 million in Q3 2024, driven by exchange rate fluctuations and support for revenue growth[388] - Selling and marketing (S&M) expenses in Q3 2025 were $656 million, a 5% increase compared to Q3 2024[427] Cash Flow and Financial Position - Free cash flow generated in Q3 2025 was $515 million, down from $922 million in Q3 2024, primarily due to lower cash flow from operating activities[331] - Cash and cash equivalents decreased to $2,203 million as of September 30, 2025, down from $3,300 million as of December 31, 2024[516] - Total balance sheet assets increased to $39,856 million as of September 30, 2025, up from $39,326 million as of December 31, 2024[512] - The working capital balance improved to negative $2,419 million as of September 30, 2025, from negative $2,837 million as of December 31, 2024, primarily due to higher inventory levels and increased accounts receivables[513] - Total debt was $16,790 million, a decrease from $17,783 million as of December 31, 2024, mainly due to the repayment of senior notes[519] Currency Exposure - Approximately 41% of revenues in Q3 2025 were denominated in currencies other than the U.S. dollar, exposing the company to significant foreign currency risks[444] - In the first nine months of 2025, approximately 45% of revenues were denominated in currencies other than the U.S. dollar, exposing the company to significant foreign currency risks[506] - Exchange rate movements positively impacted overall revenues by $53 million but negatively impacted operating income by $29 million compared to the first nine months of 2024[508]

Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent quarter, what's driving growth, and much more. ...

Core Insights - Teva Pharmaceuticals' shares surged following a strong Q3 performance, driven by growth in its branded drug portfolio, which includes treatments for schizophrenia and migraines [1][22] - The company has transitioned from a generics-focused business to a biopharma company, with its innovative portfolio growing by 33% in Q3 [3][13] - Teva's revenue guidance was adjusted, lowering the high end while raising the low end of earnings guidance, indicating confidence in future performance [1][4] Financial Performance - The innovative portfolio's growth included a 38% increase in one segment and a 90% increase in another, showcasing strong demand and competitive positioning [3][7] - The migraine treatment Ajobi grew by 19% across all regions, reflecting Teva's ability to compete effectively in a mature market [11][12] - The company reported over $800 million in sales from its innovative portfolio in Q3, contributing to overall profitability and shareholder value [14] Strategic Outlook - Teva's pivot to growth strategy initiated in 2023 aims to maintain growth with targets set for 2027, including a mid-single-digit CAGR and a net debt to EBITDA ratio of less than two [15][16] - The company has a robust pipeline of new drugs, with launches planned for the coming years, including treatments for rare diseases [17][18] - Teva's generics business remains strong, with no significant product losses expected, positioning the company favorably in the current market environment [21][22]

Core Insights - Teva Pharmaceutical Industries Limited reported a return to profitability in Q3, with a net profit of $433 million, or $0.37 per share, compared to a net loss of $437 million, or $0.39 per share, in the same quarter last year [1] - The company's net revenue increased by 1 percent in local currency terms and 3 percent year-over-year to $4.48 billion from $4.33 billion [1] Stock Performance - Teva's shares surged 24.91 percent to $21.75, with the stock fluctuating between $22.71 and $24.90 during the trading session [2] - The stock opened at $23.06 and was last seen at $24.67, compared to the previous close of $20.46, with approximately 31.8 million shares traded, more than three times the typical volume of 10 million [2] Historical Stock Fluctuation - Over the past 52 weeks, Teva's stock has fluctuated between $12.47 and $24.90 [3]

Market Performance - The Tel Aviv Stock Exchange saw an increase, with the Tel Aviv 35 Index rising by 1.02% to 3,350.98 points and the Tel Aviv 125 Index increasing by 0.82% to 3,410.08 points [1] - The BlueTech Global Index experienced a slight decline of 0.05% to 597.86 points, while the All Bond corporate bond index also fell by 0.05% to 597.86 points [1] - Total turnover in equities reached NIS 3.84 billion, and in bonds, it was NIS 4.13 billion [1] Foreign Exchange Rates - The shekel-dollar rate was set at NIS 3.250/$, reflecting a decrease of 0.276% from the previous day [2] - The shekel-euro rate was established at NIS 3.783/€, down by 0.424% [2] Company Highlights - Teva Pharmaceutical Industries Ltd. led the market with a significant rise of 17.19%, attributed to strong third-quarter results and an upward revision of its 2025 guidance [3] - Other notable gainers included Menora Mivtachim, which rose by 2.67%, and Clal Insurance Enterprise Holdings, which increased by 2.12% [3] - Tower Semiconductor and Delek Group both saw an increase of 1.19%, while Ormat Technologies rose by 1.85% [3] Company Declines - Bank Leumi and Bank Hapoalim experienced declines of 0.63% and 0.53%, respectively [4] - Mizrahi Tefahot Bank fell by 0.18%, and Israel Discount Bank decreased by 0.70% [4] - Enlight Renewable Energy had the largest drop on the Tel Aviv 35 Index, falling by 3.15% [4] - Other companies that saw declines include Nova Ltd. (1.59%), Elbit Systems Ltd. (1.18%), and Nice (1.34%) [4]

Financial Performance - Teva Pharmaceutical Industries Ltd. reported total revenue of $4.48 billion for Q3 2025, exceeding analysts' expectations of $4.35 billion [1] - Revenues increased by 3% year-over-year in U.S. dollars, or 1% in local currency [1] - Adjusted earnings were reported at 78 cents per share, surpassing the consensus of 66 cents and up from 69 cents a year ago [4] Key Product Performance - Sales of Austedo, a drug for Huntington's disease, rose by 38% to $618 million, with an increased revenue outlook for 2025 of $2.05 billion to $2.15 billion [2] - Ajovy, a migraine treatment, achieved sales of $168 million, reflecting a 19% increase in local currency year-over-year, with a reaffirmed 2025 revenue outlook of $630 million to $640 million [2] - Uzedy, a schizophrenia drug, generated revenues of $43 million, up 24%, with a reaffirmed 2025 revenue outlook of $190 million to $200 million [3] Guidance and Outlook - Teva raised its fiscal year 2025 adjusted earnings guidance from $2.50-$2.60 per share to $2.55-$2.65, compared to the consensus of $2.58 [5] - The company narrowed its 2025 sales guidance from $16.8 billion-$17.2 billion to $16.8 billion-$17 billion, against a consensus of $16.89 billion [5] Market Position and Stock Performance - Teva's stock increased by 18.23% to $24.19 following the earnings report [6] - The CEO indicated that the company is well-positioned for potential U.S. tariffs, with nine manufacturing plants in operation [6]

Core Insights - Teva Pharmaceutical Industries Ltd. stock increased by 12% following the release of stronger-than-expected third-quarter results [1] - The growth was primarily driven by robust performance in its branded drug portfolio [1] Financial Performance - The third-quarter results exceeded market expectations, indicating a positive trend in the company's financial health [1] - The specific figures related to revenue or profit were not disclosed in the provided content, but the overall performance was highlighted as strong [1]

Core Viewpoint - Teva Pharmaceuticals (TEVA.US) experienced a pre-market surge of nearly 13%, reaching $23.10, following a strong Q3 earnings report that exceeded market expectations [1] Financial Performance - Q3 revenue for Teva Pharmaceuticals was $4.48 billion, surpassing market expectations of $4.34 billion [1] - Adjusted earnings per share (EPS) for Q3 were $0.78, exceeding the market forecast of $0.68 [1] Future Guidance - The company projected its full-year revenue for fiscal year 2025 to be in the range of $16.8 billion to $17 billion, aligning closely with FactSet's estimate of $16.83 billion [1] - Teva raised its guidance for adjusted EPS for fiscal year 2025 from a range of $2.50-$2.60 to $2.55-$2.65, with analyst expectations at $2.58 [1]